Brodalumab Doubled Psoriatic Arthritis ResponsesBrodalumab Doubled Psoriatic Arthritis Responses

Brodalumab increased ACR 20 responses from 18% to 37% and 39% in patients with psoriatic arthritis; response rates continued to rise to week 24. Medscape Medical News
Source: Medscape Rheumatology Headlines - Category: Rheumatology Tags: Rheumatology News Source Type: news